Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Study of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
2023-503550-13-00Phase 2Authorised
- Sponsor
- Dren Bio
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2 trial of DR-01 in large granular lymphocyte leukemia and Cytotoxic Cutaneous T-Cell Lymphoma (CTCL), sponsored by Dren Bio. Planned start Jul 2023; status: authorised.
02
Drugs
DR-01
03
Conditions
large granular lymphocyte leukemiaCytotoxic Cutaneous T-Cell Lymphoma (CTCL)
Beyond the preview
Go deeper on 2023-503550-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503550-13-00.